Welcome to our dedicated page for BridgeBio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on BridgeBio Pharma stock.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a pioneering commercial-stage biopharmaceutical company that specializes in the discovery, creation, and delivery of transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Established in 2015, the company is headquartered in Palo Alto, California. BridgeBio's mission is to address significant unmet medical needs through genetic medicine by leveraging a comprehensive pipeline of development programs that span from early-stage scientific research to late-stage clinical trials.
The company's core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy. BridgeBio’s innovative approach involves systematically mapping the genetic disease landscape to identify promising therapeutic assets. Their proprietary platform and management expertise are harnessed to accelerate the development of these early-stage assets into clinically impactful treatments.
BridgeBio’s robust pipeline boasts several notable programs:
- Acoramidis (AG10): Aiming to treat transthyretin amyloid cardiomyopathy (ATTR-CM), this next-generation, orally-administered TTR stabilizer has shown positive results in the Phase 3 ATTRibute-CM trial. The New Drug Application (NDA) for acoramidis has been accepted by the FDA, with a target decision date set for November 29, 2024.
- Infigratinib: Targeting achondroplasia and hypochondroplasia, this FGFR1-3 inhibitor aims to address skeletal dysplasias. The PROPEL 2 Phase 2 trial has demonstrated significant and sustained increases in growth velocity.
- BBP-418: Designed for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), this glycosylation substrate is under Phase 3 trials, with the potential for accelerated approval based on recent interactions with the FDA.
BridgeBio's track record includes successful capital raises, strategic partnerships, and a series of public offerings that have strengthened its financial positioning. The company recently completed a $200 million private financing for its oncology subsidiary, BridgeBio Oncology Therapeutics, to accelerate the development of its precision oncology pipeline.
Key recent developments include:
- The initiation of a comprehensive equity grants program to attract top talent in the biopharmaceutical industry.
- Positive results from multiple clinical trials, including significant improvements in health-related quality of life measures for patients with ATTR-CM treated with acoramidis.
- Ongoing collaborations with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets in international markets.
BridgeBio remains committed to advancing genetic medicine and delivering groundbreaking therapies to improve patient lives. For more information, visit bridgebio.com and follow them on LinkedIn and Twitter.
BridgeBio Pharma (BBIO) has completed the acquisition of Eidos Therapeutics, strengthening its clinical and commercial capabilities. This merger, approved by stockholders, focuses on acoramidis, a therapy targeting transthyretin amyloidosis (ATTR), which impacts over 400,000 people globally. BridgeBio anticipates significant data releases for its core programs in 2021 and 2022, with plans to launch two drugs if approved. Eidos shareholders can receive either 1.85 BBIO shares or $73.26 in cash for each Eidos share.
BridgeBio Pharma announced the pricing of $650 million of 2.25% convertible senior notes due 2029, up from a previously planned $400 million. The offering includes an option for initial purchasers to buy an additional $97.5 million in notes, with closing expected on January 28, 2021. These unsecured notes will bear interest at 2.25% annually and have a conversion price of approximately $97.04 per share, representing a 47.5% premium over the January 25 closing price of $65.79. Net proceeds are intended for general corporate purposes, including share repurchases and research funding.
BridgeBio Pharma (Nasdaq: BBIO) announced its plans to offer $400 million in convertible senior notes due 2029, potentially increasing by another $60 million through initial purchasers. The notes will be senior unsecured obligations, bearing interest semi-annually, with specific conversion conditions. Proceeds will fund capped call transactions, share repurchases up to $50 million, and general corporate purposes, including R&D and clinical development. However, the company will not redeem the notes before February 2026, and potential market reactions from related derivative transactions could impact stock prices.
BridgeBio Pharma and Eidos Therapeutics announced that their stockholders approved the acquisition of Eidos by BridgeBio. The merger, expected to close around January 26, 2021, allows Eidos shareholders to choose between receiving 1.85 shares of BridgeBio or $73.26 in cash for each share of Eidos. The cash consideration will be capped at $175 million and prorated if necessary. Both companies aim to leverage Eidos's investigational therapy, acoramidis, targeting transthyretin amyloidosis to enhance value for patients and investors.
BridgeBio Pharma (Nasdaq: BBIO) is set to acquire Eidos Therapeutics (Nasdaq: EIDX) with a transaction expected to close around January 26, 2021. This acquisition is subject to stockholder approvals during special meetings scheduled for January 19, 2021. Eidos shareholders can choose to receive either 1.85 shares of BridgeBio's stock or $73.26 in cash for each Eidos share they own, with the cash portion capped at $175 million. Proxy advisory firms recommend voting in favor of the merger.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on January 4, 2021, the grant of 4,126 restricted stock units to six new employees under its 2019 Inducement Equity Plan, compliant with Nasdaq Listing Rule 5635(c)(4). This plan, adopted in November 2019, aims to provide compensation incentives to attract talent within the biopharmaceutical sector. Founded in 2015, BridgeBio focuses on developing transformative medicines targeting genetic diseases and cancers with genetic drivers, boasting a pipeline of over 20 development programs.
BridgeBio Pharma (NASDAQ: BBIO) has formed a three-year partnership with UC San Francisco (UCSF) to enhance the development of therapies for genetically driven diseases. This collaboration builds on a six-month pilot and aims to expedite the clinical translation of academic innovations into marketable treatments. BridgeBio intends to leverage UCSF's scientific expertise to efficiently bring new medicines to patients. Both organizations express enthusiasm about the partnership, emphasizing the importance of academia-industry collaborations in advancing medical research.
BridgeBio Pharma and Maze Therapeutics have launched a joint venture, Contour Therapeutics, aimed at advancing precision medicine for genetically defined cardiovascular diseases. This partnership leverages Maze's genetic drug discovery and BridgeBio's expertise in cardiac drug development. Initially, they will develop treatments for a specific genetically defined heart failure type. The collaboration builds on significant progress in targeting genetic causes of cardiovascular disease, aiming to innovate treatment approaches for this leading global health issue.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on December 1, 2020, the granting of stock options and restricted stock units to 15 new employees. A total of 15,351 stock options were granted at an exercise price of $51.13, along with 21,092 restricted stock units. This initiative was executed under the 2019 Inducement Equity Plan, aimed to incentivize new hires in compliance with Nasdaq Listing Rule 5635(c)(4). Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases and has over 20 development programs in its pipeline.
BridgeBio Pharma has announced the FDA's acceptance of their New Drug Application (NDA) for infigratinib, an oral FGFR1-3 selective inhibitor aimed at treating cholangiocarcinoma, a rare bile duct cancer. The NDA has been granted a Priority Review designation and is part of the Real-Time Oncology Review (RTOR) pilot program, expediting cancer treatments. This marks BridgeBio's second NDA acceptance, with plans for concurrent reviews in Australia and Canada through Project Orbis. Cholangiocarcinoma affects around 20,000 people annually in the U.S. and EU, with a low five-year survival rate of just 9%.
FAQ
What is the current stock price of BridgeBio Pharma (BBIO)?
What is the market cap of BridgeBio Pharma (BBIO)?
What does BridgeBio Pharma, Inc. specialize in?
What are the core focus areas of BridgeBio Pharma's pipeline?
What are some key programs in BridgeBio's pipeline?
What recent financial achievements has BridgeBio Pharma accomplished?
Has BridgeBio Pharma formed any significant partnerships?
What recent clinical trial results has BridgeBio Pharma announced?
When was BridgeBio Pharma founded?
Where is BridgeBio Pharma headquartered?
What is the therapeutic approach of BridgeBio Pharma?
How can I learn more about BridgeBio Pharma’s developments?
